ClinicalTrials.gg
Active, not recruitingNCT04628494EPCORE DLBCL-1Updated Nov 3, 2026Results posted

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 3 interventional study of Epcoritamab and Investigator's Choice Chemotherapy in Diffuse Large B-cell Lymphoma, sponsored by Genmab. Active, not recruiting at 186 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Genmab · Phase 3, Interventional, and Treatment

Updated Nov 3, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
483
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse — 16 open to participants now, 23 under way, 3 of them phase 3. epcoritamab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
2nd of 24
483 · median 41
Started
2021
the only one that year
Phase 3
3 of 24
none open now
Primary completion
2025-10
later than 0 of 22 live
Registered
3rd of 24
by date
Lead sponsor
8 of 24
Genmab

Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, this one is the 2nd largest by enrollment, is the only one that started in 2021, is one of 3 in phase 3, reaches primary completion later than 0 of the 22 other live ones, and was the 3rd registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

16 of the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse are open now, in 5 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About epcoritamab

epcoritamab: first FDA approval 2023 (EPKINLY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in size, or have come back following treatment with at least 1 prior systemic cancer therapy. All participants in this trial will be randomly assigned to receive either epcoritamab or a pre-specified investigator's choice (standard of care) chemotherapy (either rituximab + gemcitabine + oxaliplatin [R-GemOx], or bendamustine + rituximab [BR]). Participants must have failed or be ineligible to receive an autologous stem cell transplant (ASCT).

Epcoritamab will be injected under the skin. Investigator's choice chemotherapy will be given intravenously.

Trial details include:

  • The trial duration will be up to 5 years after last participant is randomized.
  • All trial participants have a 21-day screening period, a treatment period, and a follow-up period that continues until death.
  • The estimated trial duration for an individual participant depends upon the treatment arm assigned:

    • Participants who receive epcoritamab will have 28-day treatment cycles. Epcoritamab will be given once weekly for the first 3 months, then every other week for 6 months, then every 28 days until lymphoma progression or unacceptable adverse events.
    • Participants who receive investigator's choice (standard of care) chemotherapy will receive treatments either:

      • R-GemOx: On Day 1 (or Day 1 \& Day 2), and Day 15 (or Day 15 \& Day 16) every 28 days, for up to 4 months; or
      • BR: On Day 1 and Day 2 every 3 weeks for up to 4.5 months.
Read the detailed description

The trial is an open label, multi-center, global phase-3 randomized trial of epcoritamab. The goal of this randomized trial is to evaluate the efficacy of epcoritamab (GEN3013, DuoBody®-CD3xCD20) compared to investigator's choice of chemotherapy, in participants with relapsed, refractory DLBCL who have failed or are ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT). No change in chemotherapy is permitted for participants during the treatment phase of the trial.

Overall Survival (OS) is the primary endpoint in USA and in China, with the analysis population including all randomized participants. OS/Progression Free Survival (PFS) are dual-primary endpoints for rest of the world (outside US and China), with the analysis population also including all participants randomized.

The China sub-study of GCT3013-05 is registered under NCT07226752.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma

Keywords

  • double-hit DLBCL
  • triple-hit DLBCL
  • follicular grade 3B
  • transformed DLBCL
  • T-cell histiocytes-rich large B cell lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. disease and previously treated with at least 1 line of systemic antineoplastic therapy including anti-CD20 monoclonal antibody (mAb)-containing combination chemotherapy since lymphoma diagnosis
  2. One of the confirmed histologies below with CD20-positivity:

    1. DLBCL, not otherwise specified (NOS), including de novo or histologically transformed from follicular lymphoma (FL)
    2. "Double-hit" or "triple-hit" DLBCL (technically classified in World Health Organization (WHO) 2016 as high-grade B-cell lymphoma (HGBCL), with MYC and BCL2 and/or BCL6 translocations), including de novo or histologically transformed from FL
    3. FL Grade 3B
    4. T-cell/histiocyte-rich large B-cell lymphoma
  3. Performance Status (ECOG PS) score of 0-2
  4. Failed previous HDT- or not eligible for high-dose therapy autologous stem cell transplant (HDT-ASCT) at screening
  5. Participants must have detectable disease by positron emission tomography (PET) scan and measurable by computed tomography (CT) scan or magnetic resonance imaging (MRI)
  6. Acceptable renal and liver function
  7. >2 months on standard of care treatment

Main Exclusion Criteria:

  1. Primary Central Nervous System (CNS) tumor or known CNS involvement
  2. Any prior therapy with a bispecific antibody targeting CD3 and CD20
  3. Major surgery within 4 weeks prior to randomization
  4. Chemotherapy and other non- antineoplastic agents (except CD20 mAbs) within 4 weeks or 5 half-lives (whichever is shorter) prior to randomization
  5. Any investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to randomization
  6. Autologous stem cell transplant (ASCT) within 100 days of randomization
  7. Treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 100 days prior to randomization
  8. Seizure disorder requiring anti-epileptic therapy
  9. cardiac disease
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
483 participants (actual)

Study arms

  • Experimental
    Epcoritamab (GEN3013; DuoBody®CD3xCD20)

    Epcoritamab will be administered in Cycles of 28 days until any of the discontinuation criteria is met

    Biological: Epcoritamab

  • Active comparator
    Investigator's choice of chemotherapy

    R-GemOx will be administrated in Cycles of 28 days until maximum cycles completion or any of the discontinuation criteria is met BR will be administrated in Cycles of 21 days until maximum cycles completion or any of the discontinuation criteria is met

    Drug: Investigator's Choice Chemotherapy

Interventions

  • BiologicalEpcoritamab

    Following mandatory pre-medication, participants will be administered epcoritamab as a subcutaneous injection.

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

  • DrugInvestigator's Choice Chemotherapy

    Following mandatory pre-medication, participants will be administered intravenously either BR or R-GemOx.

    Also known as: BR or R-GemOx

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to date of death due to any cause. Participants who were still alive at the clinical cut-off date for the analysis were censored at the last date known to be alive.

    Time frame: Up to approximately 4 years, 9 months

07

Results

Posted Nov 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneEpcoritamabInvestigator's Choice (IC)
Started241242
Received at least 1 dose of trial treatment236237
Completed00
Not completed241242
Withdrew: Death161161
Withdrew: Lost to follow-up02
Withdrew: Withdrawal by subject517
Withdrew: Ongoing in trial7562

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from the date of randomization to date of death due to any cause. Participants who were still alive at the clinical cut-off date for the analysis were censored at the last date known to be alive.

Time frame:
Up to approximately 4 years, 9 months
Reported as:
Median · months
Overall Survival (OS)
monthsEpcoritamabInvestigator's Choice (IC)
Overall Survival (OS)11.3 (7.8 to 15.7)10.3 (9.0 to 12.5)
Statistical analysis
  • Epcoritamab vs Investigator's Choice (IC) · Stratified log-rank test · p = 0.7285 · Stratified hazard ratio: 0.96 · 95% CI 0.77 to 1.20

Adverse events

Collected over Up to approximately 4 years, 9 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epcoritamab162/241 (67.2%)163/236 (69.1%)229/236 (97%)
Investigator's Choice (IC)169/242 (69.8%)77/237 (32.5%)224/237 (94.5%)
Most frequent serious events
Showing 10 of 194
Most frequent serious events
EventEpcoritamabInvestigator's Choice (IC)
Cytokine release syndromeImmune system disorders62/2360/237
Covid-19Infections and infestations44/23615/237
PneumoniaInfections and infestations16/2365/237
PyrexiaGeneral disorders and administration site conditions12/2361/237
Covid-19 pneumoniaInfections and infestations8/2361/237
Urinary tract infectionInfections and infestations6/2360/237
Immune effector cell-associated neurotoxicity syndromeNervous system disorders6/2360/237
Pneumonia bacterialInfections and infestations5/2361/237
Urinary retentionRenal and urinary disorders5/2360/237
Febrile neutropeniaBlood and lymphatic system disorders4/2365/237
Most frequent other events
Showing 10 of 634
Most frequent other events
EventEpcoritamabInvestigator's Choice (IC)
AnaemiaBlood and lymphatic system disorders57/23684/237
Cytokine release syndromeImmune system disorders76/2360/237
NauseaGastrointestinal disorders32/23673/237
Platelet count decreasedInvestigations17/23671/237
NeutropeniaBlood and lymphatic system disorders54/23660/237
PyrexiaGeneral disorders and administration site conditions55/23630/237
ThrombocytopeniaBlood and lymphatic system disorders25/23654/237
Covid-19Infections and infestations51/23613/237
Neutrophil count decreasedInvestigations30/23649/237
DiarrhoeaGastrointestinal disorders46/23629/237

Baseline characteristics

Intent-to-Treat (ITT) population included all randomized participants.

Age, Categorical
Age, Categorical(Participants)EpcoritamabInvestigator's Choice (IC)Total
<=18 years000
Between 18 and 65 years5673129
>=65 years185169354
Age, Continuous
Age, Continuous(years)EpcoritamabInvestigator's Choice (IC)Total
Mean69.9 ± 9.968 ± 11.869 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)EpcoritamabInvestigator's Choice (IC)Total
Female110100210
Male131142273
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EpcoritamabInvestigator's Choice (IC)Total
Hispanic or Latino11920
Not Hispanic or Latino187193380
Unknown434083
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EpcoritamabInvestigator's Choice (IC)Total
American Indian or Alaska Native000
Asian5574129
Black or African American134
Native Hawaiian or Other Pacific Islander000
Not Reported443882
Other000
Unknown011
White141126267
Region of Enrollment
Region of Enrollment(Participants)EpcoritamabInvestigator's Choice (IC)Total
Australia7512
Austria123
Belgium141731
Canada134
Denmark7411
Finland415
France373370
Germany549
Hungary11920
Israel314
Italy141125
Japan234265
South Korea191736
Netherlands2810
Norway7310
Poland10717
Russia257
Singapore4711
Spain202040
Sweden112
Taiwan8715
Turkey201838
United Kingdom161329
United States549
08

Study locations

186 sites

Showing the first 100 of 186 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Oct 2025, 57 months.

Results were first posted in Nov 2026, 1 year after primary completion.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 57 months is close to that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2020
First posted
Nov 13, 2020
StartActual
Jan 13, 2021
Primary completionActual
Oct 13, 2025
CompletionEst.
Apr 2028
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameOverall Survival (OS)Up to approximately 5 years → Up to approximately 4 years, 9 months
  • DescriptionOverall Survival (OS): how it is measured was reworded
Nov 3, 2026
Documents
Secondary outcomes
12 removed
What changed in the outcomes
  • RemovedProgression Free Survival (PFS)Time frame: Up to approximately 5 years
  • RemovedOverall Response Rate (ORR)Time frame: Up to approximately 5 years
  • RemovedComplete Response (CR) RateTime frame: Up to approximately 5 years
  • RemovedDuration of Response (DOR)Time frame: Up to approximately 5 years
  • RemovedTime to Response (TTR)Time frame: Up to approximately 5 years
  • RemovedDuration of Minimal Residual Disease (MRD) Negative StatusTime frame: Up to approximately 5 years
  • RemovedRate of MRD Negative StatusTime frame: Up to approximately 5 years
  • RemovedTime to Next Anti-lymphoma Therapy (TTNT)Time frame: Up to approximately 5 years
  • RemovedNumber of Participants with Adverse Events (AEs)Time frame: Up to approximately 5 years
  • RemovedNumber of Participants with Dose Interruptions and DelaysTime frame: Up to approximately 5 years
  • RemovedNumber of Participants with an Anti-epcoritamab Antibody ResponseTime frame: Up to approximately 5 years
  • RemovedChanges from Baseline in Lymphoma Symptoms as Measured by the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)Time frame: Baseline up to approximately 5 years
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Results posted
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameOverall Survival (OS)Up to approximately 5 years → Up to approximately 4 years, 9 months
    • DescriptionOverall Survival (OS): how it is measured was reworded
    Secondary outcomes 12 removed
    What changed in the outcomes
    • RemovedProgression Free Survival (PFS)Time frame: Up to approximately 5 years
    • RemovedOverall Response Rate (ORR)Time frame: Up to approximately 5 years
    • RemovedComplete Response (CR) RateTime frame: Up to approximately 5 years
    • RemovedDuration of Response (DOR)Time frame: Up to approximately 5 years
    • RemovedTime to Response (TTR)Time frame: Up to approximately 5 years
    • RemovedDuration of Minimal Residual Disease (MRD) Negative StatusTime frame: Up to approximately 5 years
    • RemovedRate of MRD Negative StatusTime frame: Up to approximately 5 years
    • RemovedTime to Next Anti-lymphoma Therapy (TTNT)Time frame: Up to approximately 5 years
    • RemovedNumber of Participants with Adverse Events (AEs)Time frame: Up to approximately 5 years
    • RemovedNumber of Participants with Dose Interruptions and DelaysTime frame: Up to approximately 5 years
    • RemovedNumber of Participants with an Anti-epcoritamab Antibody ResponseTime frame: Up to approximately 5 years
    • RemovedChanges from Baseline in Lymphoma Symptoms as Measured by the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)Time frame: Baseline up to approximately 5 years
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04628494
Lead sponsor
Genmab
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Nov 13, 2020
Start date
Jan 13, 2021
Primary completion
Oct 13, 2025
Completion
Apr 2028 (estimated)
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epcoritamab

Start the discussion